BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
SBFM upcoming catalysts
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.: 4 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (2 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 1 FDA event(s). Subscribe to SBFM (.ics).
Drugs: HEC585 A, HEC585 B
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|
| No upcoming PDUFA date or AdCom found. |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| 2026-12 est. | P2 | Sunshine Lake Pharma Co., Ltd. SBFM | NCT05139719 A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Dis | Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) | recruiting | 110 |
| 2027-01-14 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT07261644 A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) | Ankylosing Spondylitis | recruiting | 500 |
| 2027-02 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06323213 Efficacy and Safety Study of 610 in Patients With Severe Asthma | Asthma | recruiting | 480 |
| 2027-02 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06680947 A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma | Asthma | active not recruiting | 225 |
FDA decision events, last 12 months
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| 2026-06-30 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT07042126 Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | recruiting | 180 |
| 2026-05-25 | P1/P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06324812 Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | completed | 128 |
| 2025-12 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06639295 A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps | Sinusitis; Nasal Polyps | active not recruiting | 243 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.